Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Study Summary

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions / Drugs

ALLO-715 ALLO-647 Fludarabine Cyclophosphamide Nirogacestat

View on ClinicalTrials.gov ↗

Sponsor

ALLO

Allogene Therapeutics

Cell Therapy

C55/100

Study Details

Enrollment132 participants

Primary Completion—

Lead SponsorAllogene Therapeutics

Data Retrieved2026-04-11 02:53:23.198064+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.